

Barcelona, Spain
June 11, 2021

Almirall appoints Dr. Karl Ziegelbauer as Chief Scientific Officer

- Dr. Ziegelbauer has three decades of leadership experience in drug discovery and joins Almirall from Bayer Pharmaceuticals, where he most recently served as Senior Vice President and Head of Open Innovation & Digital Technologies
- Dr. Ziegelbauer's appointment will be effective July 7, 2021, and he will be reporting directly to Almirall's CEO, Gianfranco Nazzi. He will also be a member of the company's Management Board

BARCELONA, Spain. June 11, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced today the appointment of **Dr. Karl Ziegelbauer** as **Chief Scientific Officer (CSO)**, effective July 7, 2021.

Dr. Ziegelbauer joins Almirall from Bayer Pharmaceuticals, where he most recently served as Senior Vice President and Head of Open Innovation & Digital Technologies. Almirall's new CSO is a recognized industry leader and he brings with him three decades of leadership experience in drug discovery in international markets such as Germany, Japan, and the United States. He has developed most of his career at Bayer Pharmaceuticals and he has been assuming positions of increasing responsibility, holding Senior Vice President roles in various medical research fields. His experience encompasses different specialties such as oncology, cardiovascular diseases, anti-infectives, and immunology/inflammation.

In his new role at Almirall, Dr. Ziegelbauer will report directly to Gianfranco Nazzi, Almirall's Chief Executive Officer (CEO), and he will also be a member of the company's Management Board. He will be responsible for building strategic partnerships and developing and expanding Almirall's R&D pipeline in Medical Dermatology.

"At Almirall, we are committed to developing breakthrough products in the field of Medical Dermatology to address patient's unmet needs. We are convinced that with the appointment of Dr. Karl Ziegelbauer as our new CSO we will reinforce our pipeline, making a positive difference to patients' health", states **Gianfranco Nazzi, Almirall's Chief Executive Officer**.

Dr. Ziegelbauer is trained in biochemistry and molecular biology and holds a PhD in Biochemistry from the University of Tübingen (Germany). He has acquired extensive experience in leading large, global R&D organizations in strategy and portfolio management, as well as in building strategic partnerships with leading academic research institutions resulting in significant pipeline progression impact. He has co-authored more than 50 scientific publications covering basic research as well as drug discovery topics.

"I am thrilled to join such a dedicated, dynamic, and patient-focused team and be part of the journey to consolidate Almirall as a leader in Medical Dermatology", adds **Dr. Karl Ziegelbauer**.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com

Media contact:

Tinkle

Pilar Colomer

pcolomer@tinkle.es

Phone: (+34) 93 545 12 51

Investors' Relations contact

Almirall

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall

Maria Duro

maria.duro@almirall.com

Phone: (+34) 671 580 492

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication, click [here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.